Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis
Explore this paper's citation graph
Summary
The aim of this study was to determine whether losartan can influence the early phase of fibrogenesis in an animal model of NASH.
- Type
- article
- Published
- 2007-06-01
- Cited by
- 41
- References
- 30
- OpenAlex
- https://openalex.org/W1985555579
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:33012563
Keywords
Losartan, Internal medicine, Medicine, Cirrhosis, Fibrosis
References
- Treatment strategies in nonalcoholic fatty liver disease
- Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study.
- Correlation Between Stellate Cell Activation and Serum Fibrosis Markers in Choline-Deficient l-Amino Acid-Defined Diet-Induced Rat Liver Fibrosis
- Nonalcoholic fatty liver disease.
- Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease
- Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver
- Antifibrotic Agents for Liver Disease
- Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats
- Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.
- Pharmacotherapy Review: Angiotensin Receptor Antagonists
- Non‐alcoholic steatohepatitis: Definitions and pathogenesis
- Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH
- Epidemiology of nonalcoholic fatty liver.
- Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.
- Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management.
- Employment of gas-liquid chromatography for the analysis of collagen amino acids in biopsy tissue.
- Liver Fibrogenesis: A New Role for the Renin–Angiotensin System
- Losartan Attenuates Bleomycin-Induced Pulmonary Fibrosis in Rats
- Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis
- Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver.
Cited by
- Genetic determinants of hepatic steatosis in man
- Experimental animal models of fatty liver disease and metabolic syndrome.
- Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.
- MODELOS ANIMALES EXPERIMENTALES DE ENFERMEDAD DE HÍGADO GRASO Y SÍNDROME METABÓLICO
- Effect of Combined Drug Therapy and Genetic Modifiers on Hepatosteatosis and Fibrosis in a Mouse Model for Alström Syndrome
- Médicaments ayant un effet sur la fibrose hépatique
- Investigación de nuevas estrategias terapeúticas para la inflamación y la fibrosis hepática.
- Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?
- Deletion of angiotensin II type I receptor reduces hepatic steatosis.
- AT1 receptor blockade delays postlactational mammary gland involution: a novel role for the renin angiotensin system
- Early detection of steatohepatitis in fatty rat liver by using MR elastography.
- Antifibrotic activity of anisodamine in vivo is associated with changed intrahepatic levels of matrix metalloproteinase‐2 and its inhibitor tissue inhibitors of metalloproteinases‐2 and transforming growth factor β1 in rats with carbon tetrachloride‐induced liver injury
- Fatty liver and lipotoxicity.
- Liver Fibrogenesis: A New Role for the Renin–Angiotensin System
- Current management of patients with nonalcoholic fatty liver disease
- Pathogenesis of liver cirrhosis.
- Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion
- Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.
- Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.
- Angiotensin converting enzyme (ACE D/I) polymorphism and its relation to liver fibrosis progression in Egyptian patients with chronic hepatitis C virus infection
Related papers
- Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats.
- Chronic Hypotensive Effects of Losartan Are Not Dependent on the Actions of Angiotensin II at AT 2 Receptors
- Study the Nephro-protective Effects of Losartan on Rats
- Effect of angiotensin II on the remodeling of aorta in spontaneously hypertensive rats
- Effect of losartan on myocytes in myocardium-infarcted rats
- Losartan-induced hepatic injury.
- Hydroxyproline fractions in serum and urine of rats during wound healing
- Antitumor effects of losartan in EAC mice
- PP062—Variable approaches in europe to the availability of generic losartan; implications for the future
- Losartan prevents impairment of learning and memory induced by chronic mild and unpredictable stress in rats